Prostacel (Alprostadil) Injection

Generic brands for Alprostadil Injection Available in India Brand Name Prostacel Generic Name Alprostadil Strength 500mg Manufacturer Celon Laboratories Ltd  

Description

Description

This page contains brief details about the drug alprostadil, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

The U.S. FDA approved Sotalol in 1996 and used to treat erectile dysfunction (ED), peripheral arterial disease (PAD), patent ductus arteriosus (PDA) in Infants and also for diagnostic purposes.

Mechanism of Action of Alprostadil

Alprostadil binds to specific receptors on smooth muscle cells in blood vessels and various tissues. When it binds to these receptors, it triggers biochemical events that lead to vasodilation. It relaxes the smooth muscles in blood vessel walls, particularly in the penis, when used for erectile dysfunction. It involves promoting the relaxation of smooth muscle cells, improving blood flow to specific body areas, depending on its intended use.

Uses of Alprostadil

It may be used to improve blood flow in patients with peripheral arterial disease (PAD), a condition in which blood flow to the extremities (usually the legs) is reduced. In newborns with certain heart conditions, such as PDA, it can open a blood vessel called the ductus arteriosus. It can also be used in diagnostic tests to assess blood flow in specific body areas, such as during penile Doppler ultrasound studies to evaluate erectile function.

Alprostadil Dosage available

Alprostadil is available as an injection and can be administered through intracavernosal injection (into the penis) by the healthcare provider on scheduled appointments. Your doctor will decide the most suitable dosage for your case according to your age and physical circumstances.

We can ship to :

News/Updates

References

  1. Bristol Myers Squibb, US Food & Drug Administration, [Revised on Oct 2021] [Accessed on 1st Aug 2022], https://packageinserts.bms.com/pi/pi_pomalyst.pdf
  2. Martha Q. Lacy and Arleigh R. McCurdy, Pomalidomide, Blood (2013), 122 (14): 2305–2309, https://ashpublications.org/blood/article-pdf/122/14/2305/1370038/2305.pdf
  3. Anton Wellstein, Giuseppe Giaccone, Michael B. Atkins, and Edward A. Sausville, Pathway-Targeted Therapies: Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules, Goodman & Gilman’s Pharmacological Basis of Therapeutics, 13th Edition, 2018, 1203-1236.